HCPCS Level II code A9607 identifies a therapeutic radiopharmaceutical: lutetium lu 177 vipivotide tetraxetan, billed per 1 millicurie. This code is used when administering targeted lutetium-177 radioligand therapy, an emerging modality in oncology for certain malignancies. Nationally, the code matters because radiopharmaceutical therapies involve specialized handling, administration, and reimbursement pathways that affect provider operations, payer coverage decisions, and patient access.

Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of clinical context for radioligand therapy, typical sites of care, and what to expect in billing practice for A9607.

The publication summarizes benchmark considerations, common billing and coverage themes, and recent policy trends relevant to radiopharmaceuticals. It provides operational context for coding and claims submission, highlights typical payer coverage approaches, and outlines areas where facilities and clinicians should expect administrative complexity. Data not available in the input is noted where applicable.